AAD 2019—Bermekimab shows dramatic improvement in pruritus and atopic dermatitis

  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • A multicenter study showed that bermekimab, an anti-IL-1α inhibitor, is an effective treatment of atopic dermatitis (AD) in patients with moderate-to-severe disease refractory to standard therapy.

Why this matters

  • In AD, ruptured keratinocytes produce IL-1α, which induces the inflammatory cascade and potentiates pain perception and pruritus.
  • Bermekimab may represent an important new treatment for pruritus and moderate-to-severe AD.

Key results

  • Bermekimab resulted in statistically significant improvements from baseline in all measures of disease severity after 7 weeks (P<.001 for all>
  • Percentage reductions from baseline in the high-dose 400 mg group:
    • Dermatology Life Quality Index (DLQI) (70%).
    • Eczema Area and Severity Index (EASI) (76%).
    • Global Individual Signs Score (GISS) (54%).
    • Hospital Anxiety and Depression Scale-Anxiety Subscale (HADS-AS) (65%).
    • HADS-Depression Subscale (HADS-DS) (59%).
    • Patient-Oriented Eczema Measures (POEM) (66%).
    • Severity Scoring of Atopic Dermatitis (SCORAD) (64%).
  • 75% of patients had more than 4-point improvement in pruritus Numerical Rating Scale (NRS) worst and average itch scores.
  • EASI 50 (82%).
  • EASI 75 (71%).
  • 25% of patients had more than 2-point improvement in Investigator Global Assessm­­ent (IGA) scores and reache­­d a score of 0-1 by week 7.
  • No new treatment-related adverse events were reported.

Study design

  • 38 patients received subcutaneous bermekimab injections weekly (10 patients received 200 mg for 4 weeks and 28 patients received 400 mg for 8 weeks).
  • Study was an open-label, proof-of-concept, multicenter study.
  • Funding: XBiotech Inc.


  • Small number of patients.
  • Not randomized or blinded.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.